Radiological manifestations and complications of lung and brain in Egyptian COVID-19 patients

Kholoud Hamdy El-Shourbagy*, Lamees M. Ghith and Lina T. Hablas

Abstract

Background: Coronavirus disease COVID-19 is a viral illness, currently affecting millions of people worldwide. Pneumonia is the most common extreme presentation of COVID-19 infection, manifesting by fever, dry cough, difficulty of breathing or shortness of breath and mainly ground-glass infiltrates in radiological images. Chest computed tomography (CT) has a potential role in the diagnosis, detection of complications and prognostication of coronavirus disease COVID-19. In addition to severe respiratory manifestations, there are a wide range of neurological manifestations ranging from nonspecific symptoms to necrotizing encephalopathies and stroke. Our study aimed to review lung and neurological manifestations in recent and post-COVID-19 Egyptian patients and to be familiar with magnetic resonance imaging (MRI) findings of Neuro-COVID patients.

Results: The present study included eighty COVID-19 patients with age ranged from 28 to 78 years (mean age 57.84 ± 12.58 years) who were 54 males (mean age 56.64 ± 12.50) and 26 females (mean age 48.65 ± 14.24). All our patients were with recent or previous history of COVID-19 infection and subjected to careful history taking, thorough clinical examination, routine laboratory investigations and CT examination. The reported lung manifestations included normal lung shadows, ground-glass opacifications (GGOs), consolidations, reticulation, reticulation and GGOs (crazy paving) and fibrotic-like changes. Out of eighty COVID-19 patients, twenty showed neurological manifestations ranging from nonspecific symptoms to necrotizing encephalopathies and stroke. Patients with neurological manifestation were in addition to CT submitted to magnetic resonance imaging (MRI) as appropriate. MRI done to neuro-COVID patients showed that 8/20 (40%) had no abnormalities and 12/20 (60%) had abnormalities. The most common abnormalities are infarction, major or lacunar infarction, followed by acute disseminated encephalomyelitis (ADEM), posterior reversible encephalopathy syndrome (PRES) and meningoencephalitis.

Conclusion: Old age patients, especially males, were more affected than females. Lung manifestations are common in COVID-19 patients than neurological manifestations. The presence of fibrotic changes in the lung could predict severe COVID-19 affection and bad prognosis. There might be an association between appearance of neurological manifestations and poor outcome in COVID-19 patients.

Keywords: COVID-19, Lung, Neurological manifestations, ADEM = acute disseminated encephalomyelitis, PRES = posterior reversible encephalomyelitis syndrome

*Correspondence: khokha.hamdy@yahoo.com
Lecturer of Diagnostic Radiology, Department of Medical Imaging and Interventional Radiology, Faculty of Medicine, Tanta University, Tanta, Egypt

Background

Coronavirus disease 2019 (COVID-19) is a highly contagious viral disease that may cause, in addition to lung disease, a wide range of non-respiratory complications due to involvement of organs by the virus or due to direct or indirect complications of this infection [1].
Thromboembolic complications due to abnormal coagulation presented in patients with COVID-19 infection may occur in up to 31% of COVID-19 patients in intensive care unit (ICU) [2]. COVID-19 coagulation disorders were associated with increased morbidity and mortality [3].

Pneumonia is the most common extreme presentation of COVID-19 infection, manifesting by fever, dry cough, difficulty of breathing and various radiological CT findings [4]. Chest CT is the best imaging modality that detects different parenchymal abnormalities and disease severity in COVID-19 patients [5].

The most common findings in chest CT of COVID-19 patients are GGOs, appearance of crazy-paving pattern, consolidations, thickening of interlobular septa, reticular pattern, mixed pattern, air bronchogram sign and bronchiolectasis, among others [6].

There are several mechanisms involved in COVID-19-associated CNS dysfunction, particularly activation of inflammatory and thrombotic pathways and, in a few patients, a direct viral effect on the endothelium and the parenchyma. Thrombi are a major cause of multisystem organ dysfunction, including respiratory failure as had been previously reported [7].

Types of neurologic complications in COVID-19 patients depend on state of patients. Those with mild cases present with headache or dizziness, whereas those with severe disease can also develop an encephalopathy with agitation, confusion, impaired consciousness, seizures and signs of corticospinal tract dysfunction [8]. Ischemic stroke occurring in COVID-19 might be associated with a viral-related systemic prothrombotic state [9]. Demonstration of COVID-19 in the brain or CSF has been inconsistent in acute COVID-19. There is an association between the presence of lung and neurological manifestations and mortality [10].

The aim of the present study is to review lung and neurological manifestations and complications associated with COVID-19 infection and analyze potential mechanisms of their damage and to be familiar with MRI findings of neuro-COVID patients.

Methods

Patients
This prospective interventional study was carried out following the approval of the Research Ethical Committee, from December 2020 to April 2021, on eighty patients; age range 28–78 years with past or present history of COVID-19 infection; collected from hospitals; ICU and out-patients clinic. The inclusion criteria included confirmed COVID-19 cases with positive PCR, and patients had history of recent contact with confirmed COVID-19-infected patients. The exclusion criteria were patients with chronic thromboembolic events in chest or brain not confirmed to be COVID-19 positive and patients with previous neurocognitive disorders. All patients were subjected to careful history taking, clinical examination, routine laboratory findings, CT examination and MRI examination as well done for patients complaining of neurological manifestations (20 patients). Informed written consent was obtained from all participants that their clinical, laboratory and radiological data had to be used in the study.

Data collection
Demographic data (age, sex), medical history of comorbid diseases (diabetes mellitus, hypertension, chronic kidney disease, cardiac disease, cancer) and clinical data (presenting symptoms, risk factors and ICU admission) were collected from patients compiled and analyzed.

Methods

- Chest CT was performed at time of admission for patient in acute phase. Chest CT was performed on GE 128 slice machine. The scans were obtained while the patient in supine position at end of inspiration with hands raised above head and hold his breath. Chest CT was carefully examined for each patient by three expert radiologists which interpreted the images in conjunction.
- MRI was done using a 1.5 Tesla MR scanner (GE Healthcare). MR sequence parameters were as follows: T1-weighted images parameters; T2-weighted images parameters; and diffusion weighted images.

Image analysis
The CT severity score index was calculated for each one of the five lung lobes, by calculation of the dissemination of the chest manifestations (opacity), ground-glass opacity (GGO), consolidation, crazy-paving pattern, septal thickening and pulmonary fibrosis. The degree of consolidation and crazy-paving pattern were highly indicators for the disease severity and the disease progression/peak as formerly reported [11].

Ground-glass opacity (GGO) is an increase in the lung density, with still visible bronchial vascular bundles. On the other hand, consolidation is opacification with obscured underlying vasculature. Fibrosis was defined as parenchymal bands, irregular interfaces (bronchovascular, pleural or mediastinal), coarse reticular pattern and traction bronchiectasis [12].
To quantify the extent of pulmonary abnormalities (total lesions, GGO, consolidation, reticulation and fibrotic-like changes), a semi-quantitative CT score [13] was assigned based on the area involved in each of the five lung lobes and given a score from 1 to 5:

1. Representing less than 5% lobar involvement.
2. 5–25% lobar involvement.
3. 26–50% lobar involvement.
4. 51–75% lobar involvement.
5. 75% lobar involvement.

Then, the final score will be the summation of individual lobar scores and will be out of 25 (total score); the total lung involvement is mild $\leq 10$, moderate 11–20 and severe $\geq 20$.

Patients especially those having severe neurological manifestations had done MRI of the brain in addition to CT of chest (20 cases).

Statistics
Data of the present study were described as mean $\pm$ standard deviation (SD) or number and frequency percent. All statistical operations done using SPSS 26 (IBM, IL, USA).

Results
Demographic and participant characteristics
The present study included 80 patients having recent or previous history of COVID-19 infection presented with respiratory and neurological symptoms. Demographic and associated comorbidities in the studied patients are recorded in Table 1. Most of COVID-19 patients came with respiratory symptoms and some with neurological manifestations as well. The most common patients’ complaints were rhinitis, persistent fever ranging from mild to severe fever, sore throat, dry cough, shortness of breath, fatigue, loss of taste and smell, seizures, headache, low mood and anxiety, stroke paresis and paralysis and altered mental status (Table 2). The reported CT findings of patients are present in Table 3 and Figs. 1, 2, 3, 4, 5, 6, 7. MRI done to 20 patients with neurological manifestation showed that 8/20 (40%) complaining of loss of taste and smell (5) and others (3) with severe headache and prolonged fatigue had no abnormalities. Twelve patients (60%) had abnormalities. MRI successfully detected serious COVID complications, namely infarction 7/12 (66.7%) (major 3″25″ and lacunar infarction 4″33.3″), followed by acute disseminated encephalomyelitis (ADEM) 3 (25%), posterior reversible encephalopathy syndrome (PRES) 1/12 (8.3%) and meningoencephalitis 1 (8.3%). Correlation between CT and MRI of patients’ with respiratory and neurological manifestations is present in Table 4 (Figs. 8, 9, 10, 11).

Discussion
COVID-19 is optimized to disseminate rapidly and widely [14], primarily through the respiratory tract by droplets, respiratory secretions and direct contact [15]. Therefore, chest CT had to be performed at sites with less traffic to avoid exposure of other patients and staff.

Chest CT is an important and fast imaging tool for the diagnostic workup of infected patients. Chest CT scan can predict the severity of the disease by showing the percentage of lung involvement and thus give an idea about the prognosis of the disease. Therefore, an appropriate and optimal management would be overtaken earlier, thus decreasing patient hospitalization and mortality rate. The prevalence of chest CT abnormalities in COVID-19 is dependent on the stage and severity of the disease [16].

Table 1 Demographic and associated comorbidities in studied patients

| Characteristics                  | Number | Percent (%) |
|----------------------------------|--------|-------------|
| All patients                     | 80     | 100         |
| Age (years)                      |        |             |
| Range                            | 28–78  |             |
| Mean $\pm$ SD                    | 57.84 $\pm$ 12.58 |
| Sex, no. (%) of patients         |        |             |
| Male                             | 54     | 67.5        |
| Female                           | 26     | 32.5        |
| BMI (Kg/m²) $\text{mean} \pm \text{SD}$ | 30.4 $\pm$ 7.6 |
| Associated comorbidities         |        |             |
| Studied n (%)                    | 80     | 100         |
| No associated comorbidities      | 19     | 23.75       |
| Hypertension                     | 32     | 40          |
| Cardiac                          | 26     | 32.5        |
| Pulmonary                        | 30     | 37.5        |
| Diabetes                         | 40     | 50          |
| Hepatic                          | 10     | 12.5        |
| COVID-19 severity                |        |             |
| Mild                             | 24     | 30          |
| Moderate                         | 46     | 57.5        |
| Severe                           | 30     | 37.5        |

Multiple patients had multiple symptoms
No number, % percentage, BMI body mass index
The current study showed that COVID-19 infection affects old age males more than females, and this could be to the biological differences between men and women [17]. The old age may be attributed to the coexisting morbidities in those patients and other factors relating to aging. This agreed with results by Liu et al. [18].

Normal chest CT findings in the present study were detected in 12 (15%) in symptomatic patients and this could be attributed to early time of examination as previously reported by Adams et al. [19]. However, Wang et al. [20] found a nonnegligible number of symptomatic cases with normal chest CT findings during the later stage of the infection.

The ground-glass opacities (GGOs) whether alone 30 (37.5%) or with consolidation were the most common pattern of pulmonary changes in COVID-19 patients and were seen in 48 out of 80 (60%) patients. This coincided with previous other studies, Parry et al. [21], Omar et al. in Egypt [17] and Adnan et al. [22], who showed that ground-glass pattern was the most common CT pattern in their studies.

Consolidation alone was found in 12 (15%) in this study; this is in comparison to the findings reported by Omer et al. [17] and Adnan et al. [22] who recorded consolidation in 23% and 9% in their studies respectively. This variation could be attributed to the timing at which CT examination is performed as consolidation with or without GGO is seen in the 2nd and 3rd weeks of infection course.

CT in the present study showed singular or multiple irregular areas of GGO or consolidation or both in 60 of the 80 (65%) patients. This was similar to previous studies of Li and Xia [23], who detected GGOs or consolidation or both in 49 of the 51 (96.1%) patients.

In the remaining patients, reticular pattern appears in 6 (7.5%) as a complex network of linear opacities on CT images, which is caused by interlobular and intralobular septal thickening as a result of lymphocytes infiltration as previously reported [24]. Previous studies reported that the appearance of a reticular pattern with interlobular septal thickening is one of the most common CT findings in patients with COVID-19 [25]. The prevalence and frequency of reticular patterns may indicate increase in COVID-19 disease progression as suggested by previous researchers [26].

Some CT images of COVID-19 patients 10 (12.5%) showed the feature of fibrosis; in the shape of reticulations, bronchiectatic changes or even honeycomb patterns. However, appearance of fibrosis may indicate either that the pulmonary lesions have been absorbed or signify fibrous hyperplasia.

Fibrotic changes are progressive and may result in irreversible interstitial lung disease, which may lead to the decline of pulmonary function, worsening of symptoms, poor quality of life and early mortality as previously reported by researchers [27].

The COVID-19 outbreak primarily targets the respiratory epithelium but also has neuro-invasive potential. Indeed, neuropsychiatric manifestations, such as fatigue headache, dizziness and delirium, are consistently observed in COVID-19 [28].

### Table 2 Symptoms at presentation and no. (%) of studied patients

| Symptoms at presentation | Number | Percent (%) |
|--------------------------|--------|-------------|
| Rhinitis                 | 62     | 77.5        |
|                         | 24     | 30          |
| Mild persistent fever    | 35     | 43.75       |
|                         | 55     | 68.75       |
| Severe persistent fever  | 18     | 22.5        |
|                         | 8      | 10          |
| Sore throat and dry cough| 62     | 77.5        |
|                         | 60     | 75          |
| Fatigue and poor appetite| 14    | 17.5        |
| Difficulty of breathing  | 28     | 35          |
| Loss of taste and smell  | 32     | 40          |
| Headache                | 16     | 20          |
| Seizers                 | 24     | 30          |
| Low mood and anxiety     | 25     | 31.25       |
| Stroke, paresis and paralysis | 22 | 27.5 |
| Altered mental status    | 8      | 10          |
| Gait imbalance           | 80     | 100         |

Multiple patients had multiple symptoms

### Table 3 CT at presentation and no. (%) of studied patients

| Characteristics                  | No. of patients | Percentage (%) |
|----------------------------------|----------------|----------------|
| Normal lung shadows              | 12             | 15             |
| Presence of GGOs alone           | 30             | 37.5           |
| Presence of GGOs with consolidation | 48           | 60             |
| Presence of consolidation alone  | 12             | 15             |
| Reticulation                     | 6              | 7.5            |
| Reticulation and GGOs (crazy paving) | 11           | 13.75          |
| Fibrotic-like changes            | 10             | 100            |
| Total studied                    | 80             | 100            |

Multiple patients had multiple lung findings

No number, % percentage

The current study showed that COVID-19 infection affects old age males more than females, and this could be to the biological differences between men and women [17]. The old age may be attributed to the coexisting morbidities in those patients and other factors relating to aging. This agreed with results by Liu et al. [18].

Normal chest CT findings in the present study were detected in 12 (15%) in symptomatic patients and this could be attributed to early time of examination as previously reported by Adams et al. [19]. However, Wang et al. [20] found a nonnegligible number of symptomatic cases with normal chest CT findings during the later stage of the infection.

The ground-glass opacities (GGOs) whether alone 30 (37.5%) or with consolidation were the most common pattern of pulmonary changes in COVID-19 patients and were seen in 48 out of 80 (60%) patients. This coincided with previous other studies, Parry et al. [21], Omar et al. in Egypt [17] and Adnan et al. [22], who showed that ground-glass pattern was the most common CT pattern in their studies.

Consolidation alone was found in 12 (15%) in this study; this is in comparison to the findings reported by Omer et al. [17] and Adnan et al. [22] who recorded consolidation in 23% and 9% in their studies respectively. This variation could be attributed to the timing at which CT examination is performed as consolidation with or without GGO is seen in the 2nd and 3rd weeks of infection course.

CT in the present study showed singular or multiple irregular areas of GGO or consolidation or both in 60 of the 80 (65%) patients. This was similar to previous studies of Li and Xia [23], who detected GGOs or consolidation or both in 49 of the 51 (96.1%) patients.

In the remaining patients, reticular pattern appears in 6 (7.5%) as a complex network of linear opacities on CT images, which is caused by interlobular and intralobular septal thickening as a result of lymphocytes infiltration as previously reported [24]. Previous studies reported that the appearance of a reticular pattern with interlobular septal thickening is one of the most common CT findings in patients with COVID-19 [25]. The prevalence and frequency of reticular patterns may indicate increase in COVID-19 disease progression as suggested by previous researchers [26].

Some CT images of COVID-19 patients 10 (12.5%) showed the feature of fibrosis; in the shape of reticulations, bronchiectatic changes or even honeycomb patterns. However, appearance of fibrosis may indicate either that the pulmonary lesions have been absorbed or signify fibrous hyperplasia.

Fibrotic changes are progressive and may result in irreversible interstitial lung disease, which may lead to the decline of pulmonary function, worsening of symptoms, poor quality of life and early mortality as previously reported by researchers [27].

The COVID-19 outbreak primarily targets the respiratory epithelium but also has neuro-invasive potential. Indeed, neuropsychiatric manifestations, such as fatigue headache, dizziness and delirium, are consistently observed in COVID-19 [28].
Fig. 1  Male patient aged 62 years old with recent history of cough and mild dyspnea. Axial CT images (A, B) show ill-defined peripheral patchy areas of ground-glass densities seen at both lungs with subpleural position (white arrows) (mild severity).

Fig. 2  Male patient aged 56 years presented by loss of smell and taste with low-grade fever. Axial (A, B) and coronal (C) CT cuts show bilateral multifocal ground-glass opacities, and smaller areas of consolidation and areas of interstitial thickening giving crazy-paving appearance (white arrows) are seen involving both lung fields with peripheral/subpleural predominance (mild to moderate severity).

Fig. 3  Female patient 46 years old presented by cough, dyspnea and fever. Axial (A, B) and coronal (C) CT images show bilateral multifocal ground-glass opacities (white arrow); areas of consolidation and areas of interstitial thickening giving crazy-paving appearance (black arrow) are seen involving both lung fields with peripheral/subpleural predominance (moderate to severe severity).
In the present study, headache was the most common central CNS manifestation, while smell and taste impairment were the commonest manifestations affecting the peripheral nervous system (PNS). These findings are in agreement with the study of Agarwal et al. [29].

Brain MRI is a feasible and important imaging modality in selected patients with COVID-19 pneumonia. MRI findings of the present study showed that eight cases out of 20 patients with neurological manifestation having...
mild or moderate coronavirus infection were normal. Our results coincided with Paterson et al. [30], who showed that MRI results or cerebrospinal fluid findings might be normal or suggestive of encephalitis for patients with CNS symptoms.

In the current study, 12 patients with coronavirus infection showed infarction in 7 cases (major or lacunar). The rest of cases (five) with moderate or severe acute infection had the picture of ADEM in 3 cases, one case had PRES and one case had meningoencephalitis. Such findings were similar to previous studies that showed the correlation between severity of COVID-19 infection and MRI findings of brain. Mao et al. [8] showed that mild cases of COVID-19 present with headache or dizziness, whereas those with severe disease can also develop an encephalopathy with agitation and signs of corticospinal tract dysfunction. Paterson et al. [30] found acute COVID-19 inflammatory CNS syndromes encephalitis, acute disseminated encephalomyelitis (ADEM), myelitis and ischemic strokes. Nepal et al. [31] found that respiratory syndrome coronavirus may damage the central nervous system (CNS).

Fig. 7 Female patient aged 35 years old, with history of COVID-19 infection 3 month ago, presented by dyspnea on exertion and tachypnea. Axial (A–D) and coronal (E, F) CT images show multiple patchy areas of ground-glass density with reticular infiltration and interlobular septal thickening, associated with multiple tiny cysts (< 1 cm) (black arrows); with lower lobes predominance, these changes are consistent with post-COVID-19 interstitial lung fibrosis.
Multiple recent reports suggest that COVID-19 is associated with acute cerebrovascular disease, including intracranial hemorrhage, large-vessel occlusion, acute ischemic stroke and dural venous sinus thrombosis [32].

Thus, the presence of neurological complications could be a bad prognostic element in COVID-19 patients. In the present study, ADEM, PRES and meningoencephalitis were detected only in moderate or severe COVID-19 cases. Our results coincided with Khatoon et al. [33], who found that neurological involvement in COVID-19 patients carries a bad prognostic indication. It was associated with more frequent

| MRI findings       | CT chest findings |
|--------------------|-------------------|
|                    | Mild | Moderate | Severe | Total |
| Normal             | 5    | 3        | 0      | 8     |
| Major infarction   | 0    | 2        | 1      | 3     |
| Lacunar infarction | 1    | 1        | 2      | 4     |
| ADEM               | 0    | 1        | 2      | 4     |
| PRES               | 0    | 0        | 1      | 1     |
| Meningoencephalitis| 0    | 0        | 1      | 1     |
| Total              | 6    | 7        | 7      | 20    |

ADEM acute disseminated encephalomyelitis, PRES posterior reversible encephalopathy syndrome

![Fig. 8](image-url) Male patient aged 29 years old, with history of COVID-19 infection 1 month ago, presented by headache, weakness in right side of the body and tingling started 3 days ago. MRI brain showed well-defined callosal and pericallosal left frontal area of altered signal intensity (black arrows) denoting subacute infarction, displaying high signal intensity in DWI (A) and intermediate signal intensity in ADC map (B) denoting free diffusion. The lesion displays isointense signal in T1WI (C) and high signal intensity in FLAIR sequence (D) and T2WI (E). Axial CT chest cut (F) of the same patient shows bilateral peripheral ground-glass opacities (white arrows) (moderate severity)
need of mechanical ventilation and higher risk of mortality. In addition, Gusev et al. [34] found a relationship between the severity of COVID-19 and the severity and frequency of neurological manifestations.

Further studies needed on a large number of patients to clarify the value of chest CT for prognostication in COVID-19 and the pathogenesis and long-term prognosis of CNS involvement in patients with COVID-19, including correlation with patient outcome.

**Conclusion**
Lung manifestations are common in COVID-19 patients than neurological manifestations. The presence of fibrotic changes in the lung could predict severe COVID-19 affection and bad prognosis. There might be an association between neurological manifestations and poor outcome in COVID-19 patients.
Fig. 10  Female patient aged 40 years old known to be hypertensive with recent history of COVID-19 developed altered consciousness. MRI brain shows multiple nearly symmetrical subcortical patchy areas of altered signal intensity are seen at both high parietal and, occipital regions (black arrows) displaying high signal in FLAIR and T2 WI (A–C), free diffusion in DWI & ADC (D, E) this MRI features are suggestive of PRES (posterior reversible encephalopathy syndrome). Axial CT (F) chest cut of the same patient shows bilateral peripheral ground-glass opacities mixed with crazy-paving appearance (severe severity).

Fig. 11  Male patient aged 48 years with recent history of COVID-19 since 3 weeks presented with fever, convulsions, altered consciousness and lethargy. FLAIR and T2WI sequences (A, B) show patchy area of high signal intensity seen at right mid brain, pons, right middle cerebellar peduncle as well as right cerebellar hemisphere. Diffusion images and ADC (C, D) show free diffusion (black arrows). Axial, sagittal and coronal (E–G) post-contrast T1 images show multiple ring enhancing lesions at fore-mentioned sites, this together with enhancing nodular meningeal thickening at right cerebello-pontine angle, right ambient cistern, right meckel’s cave and right cavernous sinus (black arrows) … this picture suggestive for post-COVID-19 meningoencephalitis. Axial CT (F) chest cut of the same patient shows bilateral peripheral ground-glass opacities mixed with crazy-paving appearance (severe severity).
Fig. 11 (See legend on previous page.)
**Abbreviations**
COVID-19: Coronavirus disease 2019; CT: Computed tomography; ICU: Intensive care unit; MRI: Magnetic resonance imaging; GGOS: Ground-glass opacifications; ADEM: Acute disseminated encephalomyelitis; PRES: Posterior reversible encephalopathy syndrome; CSF: Cerebrospinal fluid; SD: Standard deviation; CNS: Central nervous system.

**Acknowledgements**
We would like to thank all people who helped us in this work including the CT and MRI technicians.

**Authors’ contributions**
KH made substantial contribution to the main research idea, design of the work, acquisition, analysis and interpretation of the data, writing of the manuscript; and revision of the work. GL contributed to the analysis of the data, interpretation of the results and summarization of the discussion. LH shared a substantial contribution to the main research idea, design of the work, acquisition, analysis and interpretation of the data; and revision of the work. All authors read and approved the final manuscript.

**Funding**
Funding was provided by Samuel Roberts Noble Foundation.

**Availability of data and materials**
All data and materials are available.

**Declarations**

**Ethics approval and consent to participate**
This prospective interventional study was carried out following the approval of the Research Ethical Committee of Faculty of Medicine, Tanta University, from December 2020 to April 2021, on eighty (80) patients, age range 28–78 years with past or present history of COVID‑19 infection presented with either respiratory or neurologic/neuropsychiatric symptoms.

**Consent for publication**
All patients included in this research gave written informed consent to publish the data contained within this study.

**Competing interests**
The authors declare that there are no competing interests.

**Received:** 26 November 2021  **Accepted:** 28 February 2022  **Published online:** 21 March 2022

**References**
1. Tang N, Bai H, Chen X et al (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. https://doi.org/10.1111/jth.14817
2. Klok FA, Krup F, MÜHA, Van M et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID‑19. Thromb Res 191:145–147
3. Chen N, Zhou M, Dong X et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:507–513
4. Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497
5. Pan F, Ye T, Sun P et al (2020) Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID‑19) pneumonia. Radiology 295(3):715–721. https://doi.org/10.1148/radiol.2020200370
6. Bao C, Liu X, Zhang H, Li Y, Liu J (2020) Coronavirus disease 2019 (COVID‑19) CT findings: a systematic review and meta-analysis. J Am Coll Radiol 17:5146-1440(2020)30262–3. https://doi.org/10.1016/j.jacr.2020.03.006
7. Algarni H, Subahi A, Shirah B (2016) Neurological complications of Middle East respiratory syndrome coronavirus: a report of two cases and review of the literature. Case Rep Neurol Med 2016:3502683
8. Mao L, Jin H, Wang M et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurall 77:1–9. Cited from Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 1 | January 2021
9. Beyrouti R, Adams ME, Benjamin L et al (2020) Characteristics of ischemic stroke associated with COVID‑19. J Neurol Neuropsychiatry Emerg Med 8:889–891
10. Moriguchi T, Harri N, Goto J et al (2020) A first case of meningitis/encephalitis associated with SARS‑Coronavirus‑2. Int J Infect Dis 94:55–58
11. Lyu P, Liu X, Zhang R et al (2020) The performance of chest CT in evaluating the clinical severity of COVID‑19 pneumonia: identifying critical cases based on CT characteristics. Invest Radiol 55(7):412–421
12. Antonio GE, Wong K, Hui D et al (2003) Thin‑section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience. Radiology 228(3):810–815. https://doi.org/10.1148/radiol.2283030726
13. Chang YC, Chu CJ, Chang SC et al (2005) Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin‑section CT. Radiology 236(3):1067–1073
14. Klompas M (2020) Coronavirus disease 2019 (COVID‑19): protecting hospitals from the invisible. Ann Intern Med 172(9):619–620
15. Guo YR, Cao QD, Hong ZS et al (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID‑19) outbreak: an update on the status. Mil Med Res 7(1):11
16. Kwé TC, Kwé RM (2020) Chest CT in COVID‑19: what the radiologist needs to know. RadioGraphics 40:1848–1865
17. Omar S, Motawea AM, Yasin R (2020) High‑resolution CT features of COVID‑19 pneumonia in confirmed cases. Egypt J Radiol Nucl Med 51(1):1–9
18. Liu K, Chen Y, Lin R, Han K (2020) Clinical features of COVID‑19 in elderly patients: a comparison with young and middle‑aged patients. J Infect 80(6):e14–e18
19. Adams HA, Kwé TC, Yakar D, Hope MD, Kwé RM (2020) Chest CT imaging signature of coronavirus disease 2019 infection: in pursuit of the scientific evidence. Chest. https://doi.org/10.1016/j.chest.06025
20. Wang Y, Dong C, Hu Y et al (2020) Temporal changes of CT findings in 90 patients with COVID‑19 pneumonia: a longitudinal study. Radiology 296(2):ES5–ES4
21. Parry AH, Wani AH, Yaseen M, Dar KA, Choh NA, Khan NA, Shah NN, Jehangir M (2020) Spectrum of chest computed tomographic (CT) findings in coronavirus disease‑19 (COVID‑19) patients in India. Eur J Radiol 129:109147
22. Adnan A, Jooi S, Hammadzadi G, Ghayad H, Ibrahim A (2020) Spectrum of chest computed tomography findings of novel coronavirus disease 2019 in Medical City in Baghdad, a case series. J Faculty Med Baghdad 62(1,2):6–12
23. Li Y, Xia L (2020) Coronavirus disease 2019 (COVID‑19): role of chest CT in diagnosis and management. AJR 214:1280–1286
24. Hansell DM, Rankier AA, MacMahon H et al (2008) Fleischner Society: glossary of terms for thoracic imaging. Radiology 246(3):697–722
25. Bai HX, Hsieh B, Xiong Z et al (2020) Performance of radiologists in differentiating COVID‑19 from viral pneumonia on chest CT. Radiology 296(2):ES5–ES4
26. Yu M, Liu Y, Xu D, Zhang R, Lan L et al (2020) Prediction of the development of pulmonary fibrosis using serial thin‑section CT and clinical features in patients discharged after treatment for COVID‑19 pneumonia. Korean J Radiol 21(6):746–753
27. Spagnolo P, Balestro E, Alliberti S et al (2020) Pulmonary fibrosis secondary to COVID‑19: a call to arms. Lancet Respir Med 8(8):750–752
28. Ellul MA, Benjamin L, Singh B et al (2020) Neurological associations of COVID‑19. Lancet Neurol 19(9):767–783. https://doi.org/10.1016/S1474-4422(20)30221-0
29. Agarwal P, Ray S, Madan A, Tyson B (2020) Neurological manifestations in 404 COVID‑19 patients in Washington State. J Neurol 268:770–772. https://doi.org/10.1007/s00415-020-10087-z
30. Paterson RW, Brown RL, Benjamin L et al (2020) The emerging spectrum of COVID‑19 neurology: clinical, radiological and laboratory findings. Brain 143:3104–3120
31. Nepal G, Rehrig JH, Shrestha GS et al (2020) Neurological manifestations of COVID‑19: a systematic review. Crit Care 24(1):421. https://doi.org/10.1186/s13054-020-03121-z
32. Jain R, Young M, Dogra S et al (2020) COVID-19 related neuroimaging findings: a signal of thromboembolic complications and a strong prognostic marker of poor patient outcome. J Neurol Sci 414:116923
33. Khatoon F, Prasad K, Kumar V (2020) Neurological manifestations of COVID-19: available evidences and a new paradigm. J Neurovirol 26(5):619–630. https://doi.org/10.1007/s13365-020-00895-4
34. Gusev EI, Martynov MY, Boyko AN et al (2021) The novel coronavirus infection (COVID-19) and nervous system involvement: mechanisms of neurological disorders, clinical manifestations, and the organization of neurological care. Neurosci Behav Physiol 51:1–8

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.